K2 Therapeutics Recognized as a 2026 Endpoints 11 HonoreeBOSTON and SINGAPORE, Sept. 25, 2026 (GLOBE NEWSWIRE) -- K2 Therapeutics (K2), a biotechnology company built for global impact, today announced that it has been named by Endpoints News as one of the 2026 Endpoints 11. Published annually, the Endpoints 11 recognizes the most promising private biotech companies in the world, celebrating innovators who are challenging conventional thinking, pursuing transformative opportunities and helping shape the future of the biotechnology industry.
K2 Therapeutics Appoints Dr. Ying Huang as Chief Executive Officer and Announces $50 Million Seed Financing-- Global biotechnology leader with deep cross-border development and capital markets expertise appointed Chief Executive Officer ---- Company built by MPM BioImpact to identify and advance transformative innovation from around the world ---- $50 million seed financing completed to support development of a growing portfolio of first- and best-in-class therapeutic candidates --
